Tumor-Absorbed Dose for Non-Hodgkin Lymphoma Patients Treated with the Anti-CD37 Antibody Radionuclide Conjugate 177Lu-Lilotomab Satetraxetan

@article{Blakkisrud2017TumorAbsorbedDF,
  title={Tumor-Absorbed Dose for Non-Hodgkin Lymphoma Patients Treated with the Anti-CD37 Antibody Radionuclide Conjugate 177Lu-Lilotomab Satetraxetan},
  author={J. Blakkisrud and A. L{\o}ndalen and A. C. Martinsen and J. Dahle and J. E. Holtedahl and T. Bach‐Gansmo and H. Holte and A. Kolstad and C. Stokke},
  journal={The Journal of Nuclear Medicine},
  year={2017},
  volume={58},
  pages={48 - 54}
}
177Lu-lilotomab satetraxetan is a novel antibody radionuclide conjugate currently tested in a phase 1/2a first-in-human dosage escalation trial for patients with relapsed CD37+ indolent non-Hodgkin lymphoma. The aim of this work was to develop dosimetric methods and calculate tumor-absorbed radiation doses for patients treated with 177Lu-lilotomab satetraxetan. Methods: Patients were treated at escalating injected activities (10, 15 and 20 MBq/kg) of 177Lu-lilotomab satetraxetan and with… Expand
Biodistribution and Dosimetry Results from a Phase 1 Trial of Therapy with the Antibody–Radionuclide Conjugate 177Lu-Lilotomab Satetraxetan
TLDR
The biodistribution study for patients treated with 177Lu-lilotomab satetraxetan revealed the highest physiologic uptake to be in the liver and spleen (besides the red marrow); the absorbed doses were found to be modest when compared with commonly assumed tolerance limits. Expand
Red Marrow–Absorbed Dose for Non-Hodgkin Lymphoma Patients Treated with 177Lu-Lilotomab Satetraxetan, a Novel Anti-CD37 Antibody–Radionuclide Conjugate
TLDR
Hematologic toxicity was more severe for patients receiving higher absorbed radiation doses, indicating that adverse events possibly can be predicted by the calculation of absorbed dose to RM from SPECT/CT images. Expand
FDG PET/CT parameters and correlations with tumor-absorbed doses in a phase 1 trial of 177Lu-lilotomab satetraxetan for treatment of relapsed non-Hodgkin lymphoma
TLDR
Increased intra-patient response with increased tumor-absorbed doses was observed for most patients, implying individual variations in radiation sensitivity or biology, and analysis does not show any correlation between tumor- absorption doses and changes in FDG PET or ceCT parameters for the included lesions. Expand
Pre-dosing with lilotomab prior to therapy with 177Lu-lilotomab satetraxetan significantly increases the ratio of tumor to red marrow absorbed dose in non-Hodgkin lymphoma patients
TLDR
RM is the primary dose-limiting organ for 177Lu-lilotomab satetraxetan treatment, and pre-dosing with l Pilotomab has a mitigating effect on RM absorbed dose. Expand
Phase 1/2a study of 177Lu-lilotomab satetraxetan in relapsed/refractory indolent non-Hodgkin lymphoma.
TLDR
177Lu-lilotomab satetraxetan may provide a valuable alternative treatment approach in relapsed/refractory non-Hodgkin lymphoma, particularly in patients with comorbidities unsuitable for more intensive approaches. Expand
Targeting B-cell malignancies with the beta-emitting anti-CD37 radioimmunoconjugate 177Lu-NNV003
TLDR
177Lu-NNV003 had a significant anti-tumour effect and a favourable toxicity profile and warrant further clinical testing in patients with CD37-expressing B cell malignancies. Expand
The therapeutic effectiveness of 177Lu-lilotomab in B-cell non-Hodgkin lymphoma involves modulation of G2/M cell cycle arrest
TLDR
Results indicate that 177Lu-lilotomab is particularly efficient in treating tumors with reduced inhibitory CDK1 phosphorylation, such as transformed FL. Expand
Monte Carlo dosimetry of a realistic multicellular model of follicular lymphoma in a context of radioimmunotherapy.
TLDR
A dosimetric methodology based on a three-dimensional in vitro model of follicular lymphoma incubated with rituximab, an anti-CD20 monoclonal antibody used in the treatment of non-Hodgkin lymphomas, which might be combined with a radionuclide to help explain the biological effects is developed. Expand
Targeting angiogenesis for radioimmunotherapy with a 177Lu-labeled antibody
TLDR
177Lu-DTPA-TRC105, when administered at a sufficient dose, is able to curtail tumor growth and provide a significant survival benefit without off-target toxicity, and could be used in combination with other treatment options to slow tumor growth allowing the other agents to be more effective. Expand
Future of Theranostics: An Outlook on Precision Oncology in Nuclear Medicine
TLDR
This review focuses on promising novel radiopharmaceuticals and describes their preclinical and clinical status and highlights Radiolabeled antibodies, such as 131I-omburtamab directed against the B7-H3 protein on the surface of neuroblastoma cells. Expand
...
1
2
...

References

SHOWING 1-10 OF 27 REFERENCES
Red Marrow–Absorbed Dose for Non-Hodgkin Lymphoma Patients Treated with 177Lu-Lilotomab Satetraxetan, a Novel Anti-CD37 Antibody–Radionuclide Conjugate
TLDR
Hematologic toxicity was more severe for patients receiving higher absorbed radiation doses, indicating that adverse events possibly can be predicted by the calculation of absorbed dose to RM from SPECT/CT images. Expand
Patient-specific, 3-dimensional dosimetry in non-Hodgkin's lymphoma patients treated with 131I-anti-B1 antibody: assessment of tumor dose-response.
TLDR
The absence of a correlation between the total-body tumor burden and overall response or toxicity suggests that tailoring the milligram amount of administered antibody to patient tumor burden is not likely to improve response or reduce toxicity. Expand
131I-Tositumomab Radioimmunotherapy: Initial Tumor Dose–Response Results Using 3-Dimensional Dosimetry Including Radiobiologic Modeling
TLDR
Improved dose–response correlations were demonstrated when EUD incorporating the cold antibody effect was used instead of the conventionally used mean tumor-absorbed dose, demonstrating the importance of 3D calculation and radiobiologic modeling when estimating absorbed dose for correlation with outcome. Expand
Tumor-Absorbed Dose Predicts Progression-Free Survival Following 131I-Tositumomab Radioimmunotherapy
TLDR
Tumor-absorbed dose, which can be estimated before therapy, can potentially be used to design radioimmunotherapy protocols to improve efficacy and is significantly predictive of improved PFS after 131I-tositumomab radioIMmunotherapy. Expand
Dosimetry for fractionated (131)I-mIBG therapies in patients with primary resistant high-risk neuroblastoma: preliminary results.
TLDR
The tumor dosimetry protocol was simple to apply and reproducible, but the errors in image quantitation needed to be evaluated, and the method is more accurate than a weight-based administration method. Expand
Targeted Cancer Therapy with a Novel Anti-CD37 Beta-Particle Emitting Radioimmunoconjugate for Treatment of Non-Hodgkin Lymphoma
TLDR
In vitro internalization studies showed that 177 Lu-HH1 internalizes faster and to a higher extent than 177Lu-rituximab which might be the reason for the better therapeutic effect of 177Lu -HH1. Expand
Initial results for Hybrid SPECT--conjugate-view tumor dosimetry in 131I-anti-B1 antibody therapy of previously untreated patients with lymphoma.
  • K. Koral, Y. Dewaraja, +7 authors R. Wahl
  • Medicine
  • Journal of nuclear medicine : official publication, Society of Nuclear Medicine
  • 2000
UNLABELLED A study of the use of 131I-labeled anti-B1 monoclonal antibody, proceeded by an unlabeled predose, for therapy of previously untreated non-Hodgkin's lymphoma patients has recently beenExpand
Dose Response of Pancreatic Neuroendocrine Tumors Treated with Peptide Receptor Radionuclide Therapy Using 177Lu-DOTATATE
TLDR
Evaluating the dose–response relationship for pancreatic neuroendocrine tumors treated with PRRT using 177Lu-DOTATATE implies a significant correlation between absorbed dose and tumor reduction. Expand
Update on hybrid conjugate-view SPECT tumor dosimetry and response in 131I-tositumomab therapy of previously untreated lymphoma patients.
  • K. Koral, Y. Dewaraja, +7 authors R. Wahl
  • Medicine
  • Journal of nuclear medicine : official publication, Society of Nuclear Medicine
  • 2003
TLDR
Patients with evaluated tumors that receive the highest tumor radiation dose are most likely to achieve a CR, and Dosimetry based on a combination of pretherapy conjugate views and intratherapy SPECT provides somewhat better correspondence between the patient's average tumor dose and his or her degree of response compared with dosimetry from prether therapy conjugates alone. Expand
Individualized dosimetry in patients undergoing therapy with 177Lu-DOTA-D-Phe1-Tyr3-octreotate
TLDR
It is concluded that SPECT dosimetry based on small VOIs is feasible and more accurate than conventional planar Dosimetry, and thus may contribute towards optimising targeted radionuclide therapy. Expand
...
1
2
3
...